Edition:
India

Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

9.30USD
14 Dec 2018
Change (% chg)

$-0.18 (-1.90%)
Prev Close
$9.48
Open
$9.39
Day's High
$9.75
Day's Low
$9.28
Volume
181,252
Avg. Vol
179,509
52-wk High
$43.98
52-wk Low
$9.05

Latest Key Developments (Source: Significant Developments)

Adamas Pharma And Unit Filed First Amended Answer Against Osmotica Pharma & Vertical Pharma
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Adamas Pharmaceuticals Inc ::ADAMAS - CO,UNIT FILED FIRST AMENDED ANSWER INCLUDING INFRINGEMENT COUNTERCLAIMS AGAINST OSMOTICA PHARMA & VERTICAL PHARMA- SEC FILING.ADAMAS PHARMACEUTICALS - AMENDED ANSWER INCLUDING INFRINGEMENT COUNTERCLAIMS IN ITS ONGOING LITIGATION CONCERNING OSMOLEX ER IN COURT.ADAMAS PHARMACEUTICALS INC - OSMOTICA FILED A COMPLAINT SEEKING A DECLARATORY JUDGEMENT OF NON-INFRINGEMENT OF MULTIPLE ADAMAS PATENTS.ADAMAS PHARMACEUTICALS INC - ADAMAS' COUNTERCLAIMS ASSERT THAT OSMOTICA HAS INFRINGED NINE ADAMAS PATENTS.  Full Article

Adamas Announces Final Results From Phase 3 Open-Label Study Of Gocovri
Thursday, 19 Apr 2018 

April 19 (Reuters) - Adamas Pharmaceuticals Inc ::ADAMAS ANNOUNCES FINAL RESULTS FROM THE TWO-YEAR PHASE 3 OPEN-LABEL STUDY OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA.SAYS PATIENTS RECEIVING GOCOVRI EXPERIENCED LONG-TERM DURABILITY FOR UP TO TWO YEARS.SAYS SAFETY PROFILE WAS CONSISTENT WITH PREVIOUSLY-PUBLISHED CONTROLLED PHASE 3 STUDIES.SAYS RESULTS DEMONSTRATED THAT GOCOVRI WAS GENERALLY WELL TOLERATED.  Full Article

Adamas Announces Proposed Public Offering Of Common Stock
Tuesday, 23 Jan 2018 

Jan 22 (Reuters) - Adamas Pharmaceuticals Inc ::ADAMAS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ADAMAS PHARMACEUTICALS INC SAYS IT PLANS TO OFFER $85 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Adamas Pharmaceuticals reports Q3 loss per share $1.04
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Adamas Pharmaceuticals Inc :Adamas Pharmaceuticals Inc reports recent achievements and third quarter 2017 financial results.Q3 loss per share $1.04.Q3 earnings per share view $-0.98 -- Thomson Reuters I/B/E/S.Adamas Pharmaceuticals Inc - ‍ expects to receive $65 million in funding from healthcare royalty partners in q4 of 2017.Adamas Pharmaceuticals Inc - ‍ believe we will be sufficiently capitalized to launch and commercialize gocovri, among others​.  Full Article

Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Adamas Pharmaceuticals Inc :Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals as of October 24 - SEC filing‍​.  Full Article

Point72 Asset Management reports 5.1 pct passive stake in Adamas Pharma‍​
Saturday, 28 Oct 2017 

Oct 27 (Reuters) - Adamas Pharmaceuticals Inc :Point72 Asset Management L.P reports a 5.1 percent passive stake in Adamas Pharmaceuticals Inc as of October 26, 2017 - SEC filing‍​.  Full Article

Adamas Pharmaceuticals says FDA recognizes orphan drug exclusivity for GOCOVRI
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Adamas Pharmaceuticals Inc ::FDA recognizes orphan drug exclusivity for Adamas’ GOCOVRI.  Full Article

Adamas Pharmaceuticals says unit entered into amended and restated API supply agreement with Moehs Ibérica
Saturday, 7 Oct 2017 

Oct 6 (Reuters) - Adamas Pharmaceuticals Inc :Adamas Pharmaceuticals says ‍on Oct 4, unit entered into amended and restated API supply agreement with Moehs Ibérica - SEC Filing.Adamas Pharma - ‍Moehs will supply to adamas amantadine hcl, active pharmaceutical ingredient in Adamas's product Gocovri extended-release capsules​.Adamas Pharmaceuticals Inc - ‍Adamas will provide Moehs with forecasts and purchase orders for quantities of API, and moehs will supply Adamas with API​.Adamas Pharmaceuticals Inc - ‍agreement has a term of 14 years​.  Full Article